BlinkLab Limited (ASX:BB1) has received $1,219,737 under the Australian Government's Research and Development Tax Incentive program, the company disclosed on 19 November 2026.

Key Points

  • BlinkLab received $1,219,737 as a non-dilutive R&D Tax Incentive refund from the Australian Government.
  • The refund relates to eligible R&D expenditure on the U.S. pilot study, the initiation of the U.S. pivotal study, and Australian clinical research including the MAGNET study collaboration with Monash University.
  • The refund is in addition to the $16.2 million cash balance reported at the end of the September 2026 quarter.
  • The company stated the funds will support its U.S. pivotal study, FDA submission expected in Q1 2027, and ongoing Australian clinical research and product development programs.

R&D Tax Incentive Refund Details

According to the filing, the $1,219,737 refund covers eligible R&D expenditure across several programs: the final stages of BlinkLab's U.S. pilot study, the initiation of its U.S. pivotal study, and clinical research activities conducted in Australia. The Australian clinical research component includes collaborative work undertaken through the MAGNET study at Monash University. The company described the refund as non-dilutive funding. BlinkLab is developing a smartphone-based neurobehavioural assessment platform for autism, and the filing states these programs support the development, validation and clinical investigation of that platform.

Cash Position and Planned Use of Funds

The filing states the refund is received on top of the $16.2 million cash balance reported at the end of the September 2026 quarter. BlinkLab disclosed that the funds will be directed toward progressing its U.S. pivotal study and FDA submission, continuing clinical research and collaborations in Australia, and broader product and regulatory development programs. The company said it is well funded to complete its U.S. pivotal study and lodge its submission to the FDA, with that submission expected in Q1 2027.

U.S. Pivotal Study and FDA Submission Timeline

BlinkLab disclosed that its U.S. pivotal study is currently underway, with the FDA submission expected in Q1 2027. The filing notes that in the United States, approximately 1 in 31 children is identified with autism, and that families commonly face long waits for specialist assessment. BlinkLab's smartphone-based diagnostic aid, BlinkLab Dx1, is described in the filing as leveraging smartphones, artificial intelligence and machine learning to capture objective, reflex-based measures to support autism identification. The company was founded by neuroscientists at Princeton University.